title: Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM.
abstract: We have evaluated the effects of repaglinide, a new non-sulphonylurea oral hypoglycaemic agent that has a stimulatory effect on insulin secretion. Forty-four patients with NIDDM, already treated with a sulphonylurea, took part in an open, randomised, group comparison study of 12 weeks duration, during which they received either repaglinide or glibenclamide twice daily. While glibenclamide had a greater effect on fasting blood glucose (10.4 to 8.6 mmol.l-1), repaglinide significantly lowered postprandial blood glucose (13.8 to 12.2 mmol.l-1). Glycosylated haemoglobin remained unchanged in both groups, and serum fructosamine showed a tendency to fall. With both treatments total cholesterol was significantly decreased after 12 weeks, while HDL-cholesterol and triglycerides did not change. Fasting plasma insulin in the repaglinide group decreased from 80 (median value) to 67 pmol.l-1; it did not change in the glibenclamide group. Two patients in the repaglinide group did not complete the study, one for personal reasons, and one because of a rise in blood glucose. No abnormal findings attributable to repaglinide were observed in clinical and laboratory examinations, and no hypoglycaemic symptoms caused by it were observed.
authors.affiliation: Department of Internal Medicine, University Hospital, University of Limburg, Maastricht, The Netherlands.
authors.forename: B H
authors.initials: BH
authors.lastname: Wolffenbuttel
authors.forename: L
authors.initials: L
authors.lastname: Nijst
authors.forename: J P
authors.initials: JP
authors.lastname: Sels
authors.forename: P P
authors.initials: PP
authors.lastname: Menheere
authors.forename: P G
authors.initials: PG
authors.lastname: Müller
authors.forename: A C
authors.initials: AC
authors.lastname: Kruseman
mesh_terms: D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D002219:Carbamates / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy; D005260:Female; D019270:Fructosamine; D005907:Gliclazide / Q000627:therapeutic use; D005905:Glyburide / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D006442:Glycated Hemoglobin / Q000032:analysis; D006595:Hexosamines / Q000097:blood; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D014044:Tolbutamide / Q000627:therapeutic use
chemical_list: D001786:Blood Glucose; D002219:Carbamates; D019270:Fructosamine; D005907:Gliclazide; D005905:Glyburide; D006442:Glycated Hemoglobin; D006595:Hexosamines; D007004:Hypoglycemic Agents; D008055:Lipids; D010880:Piperidines; D014044:Tolbutamide; C072379:repaglinide